INSM - earnings call tomorrow 8/1, on a double bottom

[weatherbill]

possible pop here on earnings tomorrow possibly....put on watch

double bot on 2 mo chart

[Evil-Eye]

Originally Posted by weatherbill

possible pop here on earnings tomorrow possibly....put on watch

double bot on 2 mo chart

Look at them lined up on the bid. Large bid small ask....hhmmm I wonder what they know.

Looks nice

[weatherbill]

insiders have accumulated shares in the last 5 form 4s in late june for .80, .78 and .71

a good sign

[weatherbill]

word is they lost a law suit recently, so better hold off for now till we see what the earning are

[weatherbill]

I'm looking for that law suit info, but I can;t find anything on it.....someone from another room said they recently lost a law suit, but can;t find anything on it.....

[Revsly]

Did it just happen in the past few days? Or are they refering to this:

March 7, 2007. Insmed Incorporated Announces Litigation Settlement
With Tercica, Inc., and Genentech, Inc. Insmed Incorporated: Tercica, Inc., and
Insmed Incorporated announced that Tercica, Insmed and Genentech, Inc. have
entered a settlement, license and development agreement that resolves all
outstanding litigation between the companies, including the patent infringement
suits brought by Tercica and Genentech against Insmed in the United States (N.D.
Cal.) and United Kingdom, and the unfair business practices suit (E.D. Virginia).
Insmed will no longer provide IPLEX to patients with severe Primary IGF-1
Deficiency and other short stature indications and will withdraw its IPLEX marketing
authorization application for severe Primary IGF-1 Deficiency in the European
Union. Through licensing and development rights granted by Tercica and
Genentech, Insmed will have freedom to operate regarding the manufacture,
development and commercialization of IPLEX for certain non-short stature
indications including severe insulin resistance, myotonic muscular dystrophy and
HIV associated adipose redistribution syndrome, subject to opt-in rights and royalty
provisions for Tercica and Genentech. Tercica and Genentech have waived the
damages award by the jury in the U.S. patent infringement litigation.

[Evil-Eye]

Insmed Reports Financial Results for Second Quarter and First Half of 2007
Thursday August 2, 9:15 am ET
Quarterly Revenues Increase to $2.3M from $210K in Prior Year; Lower SG&A Expenses Help Narrow Loss

http://biz.yahoo.com/bw/070802/20070802005297.html?.v=1

[JAM]

This one looks like it is breaking out today. last trade .677 up 7%

Good volume, approaching 50 day ma, just under .7

[JAM]

Moving up very nicely today 5%, just crossed 50day.

[JAM]

Anyone else in on this one. Great day finished @.75 12% up.

I think tomorrow we find out if this was a 2 day spike or we start a good run up.

It briefly crossed the 100 day MA (about .76), still well below 150 and 200. But today was best volume/price performance in 4-5 months.